FDA approves Eli Lilly's Taltz for psoriasis

The US Food and Drug Administration (FDA) has approved Eli Lilly’s monoclonal antibody Taltz (ixekizumab) to treat adults with moderate-to-severe plaque psoriasis, it has been announced.

Taltz’s active ingredient, ixekizumab, works by binding to a protein (interleukin (IL)-17A) that causes inflammation. This inhibits the inflammatory response that plays a role in the development of plaque psoriasis.

Julie Beitz, director of the office of drug evaluation at the FDA’s Center for Drug Evaluation and Research, said: “Today’s approval provides patients suffering from plaque psoriasis with another important treatment option to help relieve the skin irritation and discomfort from the condition.”